Products
Ascrinvacumab Biosimilar Monoclonal Antibody (ACVRL1) for Research
Pre-Made Ascrinvacumab biosimilar, Whole mAb, Anti-ACVRL1 Antibody: Anti-ACVRLK1/ALK-1/ALK1/HHT/HHT2/ORW2/SKR3/TSR-I therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ascrinvacumab (PF-03446962) is a monoclonal antibody designed for the treatment of cancer.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-032-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Ascrinvacumab biosimilar, Whole mAb, Anti-ACVRL1 Antibody: Anti-ACVRLK1/ALK-1/ALK1/HHT/HHT2/ORW2/SKR3/TSR-I therapeutic antibody |
| INN Name | Ascrinvacumab |
| Target | ACVRL1 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Duke University Medical Center;Fondazione IRCCS Istituto Nazionale dei Tumori;Pfizer;Suzhou Kintor Pharmaceuticals |
| Conditions Approved | na |
| Conditions Active | Age-related macular degeneration;Cancer;Liver Cancer |
| Conditions Discontinued | Colorectal cancer;Liver cancer;Solid tumours;Urogenital cancer |
| Development Tech | na |
About target - ACVRL1
1. Protein Serine/threonine-protein kinase receptor R3
2. Gene ACVRL1
3. Organism Homo sapiens (Human)
Function
Type I receptor for TGF-beta family ligands BMP9/GDF2 and BMP10 and important regulator of normal blood vessel development. On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. May bind activin as well.
Catalytic activity
ATP + L-threonyl-[receptor-protein] = ADP + H+ + O-phospho-L-threonyl-[receptor-protein]
EC:2.7.11.30
ATP + L-seryl-[receptor-protein] = ADP + H+ + O-phospho-L-seryl-[receptor-protein]
EC:2.7.11.30
Cofactor
Mg2+, Mn2+
